Logo image of NTUS

NATUS MEDICAL INC (NTUS) Stock Fundamental Analysis

NASDAQ:NTUS - Nasdaq - US6390501038 - Common Stock - Currency: USD

32.96  +0.03 (+0.09%)

After market: 32.96 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NTUS. NTUS was compared to 189 industry peers in the Health Care Equipment & Supplies industry. While NTUS seems to be doing ok healthwise, there are quite some concerns on its profitability. NTUS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year NTUS was profitable.
NTUS Yearly Net Income VS EBIT VS OCF VS FCFNTUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M

1.2 Ratios

Industry RankSector Rank
ROA 2.23%
ROE 2.94%
ROIC 5.05%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NTUS Yearly ROA, ROE, ROICNTUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 5 -5 10

1.3 Margins

Industry RankSector Rank
OM 7.06%
PM (TTM) 2.65%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NTUS Yearly Profit, Operating, Gross MarginsNTUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 20 40 60

6

2. Health

2.1 Basic Checks

NTUS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, NTUS has more shares outstanding
NTUS has a better debt/assets ratio than last year.
NTUS Yearly Shares OutstandingNTUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M
NTUS Yearly Total Debt VS Total AssetsNTUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M

2.2 Solvency

An Altman-Z score of 6.54 indicates that NTUS is not in any danger for bankruptcy at the moment.
NTUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.54
ROIC/WACC0.56
WACC8.98%
NTUS Yearly LT Debt VS Equity VS FCFNTUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

2.3 Liquidity

NTUS has a Current Ratio of 2.54. This indicates that NTUS is financially healthy and has no problem in meeting its short term obligations.
NTUS has a Quick Ratio of 1.90. This is a normal value and indicates that NTUS is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 1.9
NTUS Yearly Current Assets VS Current LiabilitesNTUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

5

3. Growth

3.1 Past

NTUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 147.06%, which is quite impressive.
The Earnings Per Share has been decreasing by -5.94% on average over the past years.
The Revenue has grown by 13.56% in the past year. This is quite good.
NTUS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.39% yearly.
EPS 1Y (TTM)147.06%
EPS 3Y-5.46%
EPS 5Y-5.94%
EPS Q2Q%37.5%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y-3.75%
Revenue growth 5Y4.39%
Sales Q2Q%4.26%

3.2 Future

Based on estimates for the next years, NTUS will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.74% on average per year.
Based on estimates for the next years, NTUS will show a small growth in Revenue. The Revenue will grow by 4.27% on average per year.
EPS Next Y22.4%
EPS Next 2Y15.52%
EPS Next 3Y15.29%
EPS Next 5Y15.74%
Revenue Next Year5.1%
Revenue Next 2Y4.79%
Revenue Next 3Y4.1%
Revenue Next 5Y4.27%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NTUS Yearly Revenue VS EstimatesNTUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
NTUS Yearly EPS VS EstimatesNTUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2

1

4. Valuation

4.1 Price/Earnings Ratio

NTUS is valuated quite expensively with a Price/Earnings ratio of 26.16.
The average S&P500 Price/Earnings ratio is at 29.62. NTUS is around the same levels.
The Price/Forward Earnings ratio is 20.58, which indicates a rather expensive current valuation of NTUS.
The average S&P500 Price/Forward Earnings ratio is at 22.70. NTUS is around the same levels.
Industry RankSector Rank
PE 26.16
Fwd PE 20.58
NTUS Price Earnings VS Forward Price EarningsNTUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.23
NTUS Per share dataNTUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

NTUS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as NTUS's earnings are expected to grow with 15.29% in the coming years.
PEG (NY)1.17
PEG (5Y)N/A
EPS Next 2Y15.52%
EPS Next 3Y15.29%

0

5. Dividend

5.1 Amount

No dividends for NTUS!.
Industry RankSector Rank
Dividend Yield N/A

NATUS MEDICAL INC

NASDAQ:NTUS (7/20/2022, 8:05:33 PM)

After market: 32.96 0 (0%)

32.96

+0.03 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-05 2022-05-05/amc
Earnings (Next)08-04 2022-08-04/amc
Inst Owners91.2%
Inst Owner ChangeN/A
Ins Owners0.64%
Ins Owner Change0%
Market Cap1.14B
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 26.16
Fwd PE 20.58
P/S 2.38
P/FCF N/A
P/OCF N/A
P/B 2.65
P/tB N/A
EV/EBITDA 17.23
EPS(TTM)1.26
EY3.82%
EPS(NY)1.6
Fwd EY4.86%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS13.83
BVpS12.46
TBVpSN/A
PEG (NY)1.17
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.23%
ROE 2.94%
ROCE N/A
ROIC 5.05%
ROICexc N/A
ROICexgc 9.3%
OM 7.06%
PM (TTM) 2.65%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 1.9
Altman-Z 6.54
F-Score8
WACC8.98%
ROIC/WACC0.56
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)147.06%
EPS 3Y-5.46%
EPS 5Y-5.94%
EPS Q2Q%37.5%
EPS Next Y22.4%
EPS Next 2Y15.52%
EPS Next 3Y15.29%
EPS Next 5Y15.74%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y-3.75%
Revenue growth 5Y4.39%
Sales Q2Q%4.26%
Revenue Next Year5.1%
Revenue Next 2Y4.79%
Revenue Next 3Y4.1%
Revenue Next 5Y4.27%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A